Loading
Aardvark Therapeutics, Inc. Stock: price and insider trades · United States
US·Mcap US$82.7M
No insider purchase over the last 90 days. The latest was filed 12 Dec 2025.
Aardvark Therapeutics, Inc.: what insiders have been doing
Aardvark Therapeutics, Inc. is a listed company. Filings by its managers are published through SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 6 filings came from 3 insiders.
Open-market activity splits into 2 purchases totalling €124k and 2 sales totalling €340k; 2 insiders sit on the buying side and 1 insider on the selling side. On balance, insiders were net sellers of €216k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The largest single trade was a sale of €276k by Sun Nelson, published on 11 September 2026, equal to 0.26% of the market capitalisation. The buyers include 1 finance chief and 1 chief executive.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 6 filings here. Looking back to 2025, when coverage begins, insiders filed 6 purchases and 2 sales.
Within a 30-day window, 2 purchases overlapped with buying by a second insider. Purchases made close together by different insiders form what is called a cluster. The last purchase on record was published on 12 December 2025, which is 310 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. US insiders must file a Form 4 within two business days of a trade.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
19
Thresholds
n/a
Buy Volume
€307,948
6 ops. · all time
Sell Volume
€339,844
2 ops. · all time
Who traded when
BuySaleNelson Sun2 buys2 sales
Tien-Li Lee4 buys
Since the insiders bought
- -64.8%Entry US$14.47 · Close at T+90 US$5.09
- -64.8%Entry US$14.47 · Close at T+90 US$5.09
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Aardvark Therapeutics, Inc. Buy (bullish), based on 9 analysts. Average price target: US$11.11.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.78
Analyst consensus
9 analystsBuy
US$3.00Target US$11.11(+194%)US$28.00
Income statement
EBITDA-US$62.7M
Net income-US$57.6M0.0% margin
Valuation
PER (forward)-1.6x
P/Book1.1x
Balance sheet & cash
Market capUS$82.7M
Total debtUS$441k
Free Cash Flow-US$54.3M
Debt / Equity1%
Profitability & ownership
ROE-66.0%
ROA-40.4%
% insiders15.8%
% institutions52.6%
Last declaration on 11 September 2026
Declarations19 total
33,911 shares@ US$5.0144.7% of flowCommonSEC144:0001950047-26-009373
14,754 shares@ US$5.00060.059% mcap15.2% of flowCommon Stock, par value $0.00001 per shareSEC:0001193125-26-389564:0
62,000 shares@ US$5.18030.26% mcap66.1% of flowCommon Stock, par value $0.00001 per shareSEC:0001193125-26-389564:1
42,843 shares@ US$4.9255.3% of flowCommonSEC144:0001950047-26-009316
3,000 shares@ US$14.408.8% of flowCommon StockSEC:0001193125-25-318070:0
Canonical exit: 11 Mar 2026 (T+90)
7,000 shares@ US$14.48529.2% of flowCommon StockSEC:0001193125-25-318069:0
Canonical exit: 11 Mar 2026 (T+90)
1,229 shares@ US$4.241.5% of flowCommon StockSEC:0001193125-25-241647:0
1,250 shares@ US$4.24100.0% of flowCommon StockSEC:0001193125-25-241643:0
6,500 shares@ US$9.510617.7% of flowCommon StockSEC:0001193125-25-204233:0
Canonical exit: 14 Dec 2025 (T+90)
3,500 shares@ US$9.944210.0% of flowCommon StockSEC:0001193125-25-204233:1
Canonical exit: 14 Dec 2025 (T+90)
9,000 shares@ US$7.912520.5% of flowCommon StockSEC:0001193125-25-202490:0
Canonical exit: 9 Dec 2025 (T+90)
6,000 shares@ US$8.07339.9% of flowCommon StockSEC:0001193125-25-200226:0
Canonical exit: 8 Dec 2025 (T+90)
17,209 shares@ US$4.2421.1% of flowCommon StockSEC:0001193125-25-192747:0
1,637,411 sharesCommon StockSEC:0000950170-25-023287:0
41,303 sharesCommon StockSEC:0000950170-25-023253:0
800,189 sharesCommon StockSEC:0000929638-25-000822:0
7,001 sharesCommon StockSEC:0000950170-25-023243:0
133,364 sharesCommon StockSEC:0000950170-25-023311:0
2,333,887 sharesCommon StockSEC:0000950170-25-023409:0
19 of 19 declarations
About Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. is a company focused on developing innovative treatments for specific diseases. It is listed on the XNAS market.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
